SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets close in 4 hrs 55 mins

Sanofi (SNY)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
46.41+0.51 (+1.11%)
As of 11:05AM EDT. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close45.90
Bid0.00 x
Ask0.00 x
Day's Range46.19 - 46.44
52 Week Range36.81 - 46.44
Avg. Volume1,522,990
Market Cap115.9B
PE Ratio (TTM)24.01
Earnings DateN/A
Dividend & Yield1.58 (3.46%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com18 minutes ago

    K-Mart to Sell Cheaper EpiPen Alternative

    K-Mart will charge cash paying customers $199 for a two-pack vs. Mylan's $643.

  • Business Wire3 hours ago

    New Data Suggest Positive Effects of Sanofi Genzyme’s Aubagio® (teriflunomide) on Cortical Gray Matter Atrophy

    Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data evaluating the effect of Aubagio® on cortical gray matter atrophy in patients with a first clinical episode suggestive of MS will be presented at the 69th American Academy of Neurology Annual Meeting.

  • PR Newswire3 hours ago

    Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

    BRIDGEWATER, N.J. and TARRYTOWN, N.Y., April 25, 2017 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the companies' new supplemental Biologics License Application (sBLA) for a once-monthly (every four weeks), 300 mg dose of Praluent® (alirocumab) Injection for the treatment of adults with high low-density lipoprotein (LDL) cholesterol. Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL cholesterol. The effect of Praluent on cardiovascular (CV) morbidity and mortality has not been determined.